Representatives from industry associations, companies and governing bodies yesterday said that while it is vital for the nation to participate in the Trans-Pacific Partnership (TPP) and the Regional Comprehensive Economic Partnership (RCEP), Taiwan’s biotechnology, medical and pharmaceutical sectors must first overcome several challenges before they have a chance of tapping international markets.
Taiwan’s accession to the TPP and RCEP would improve international harmonization on regulatory approval guidelines and allow the nation’s top biotechnology, pharmaceutical, and medical products and services to enter international marketplaces, experts said at a forum in Taipei.
Taiwanese companies would enjoy reduced costs of entry and risks thanks to greater levels of transparency in regulatory approval processes and assessment metrics, which are awarded to members of the trade blocs, panelists said.
As the nation vies to increase exports of active pharmaceutical ingredients and boost new drug development, which is currently estimated at less than 1 percent of the global market, domestic generic drug makers would face greater challenges, such as the more stringent intellectual property and patent laws in major markets abroad, Vice Premier Simon Chang (張善政) said.
“Due to immense development costs of developing new drugs, companies’ research findings must be protected by comprehensive patent systems to ensure their first-to-market advantage,” Savior Lifetec Corp (展旺生命科技) chairperson Sherry Ku (顧曼芹) said.
The concept of patent linkage, which prevents generic drugs from obtaining market licenses prior to the expiration of the patent term or receiving the consent of the original manufacturer is recognized in law in a number of major markets, including the US and India, and would likely be one of the conditions of joining the TPP, Ku said.
However, few Taiwanese companies are equipped to navigate the complex patent systems and obtain the required certifications, Ku said.
Taiwan’s lack of a patent linkage system has deterred foreign companies interested in the nation.
“Companies must adopt different strategies for each trade block. While innovation is vital for success in the TPP, where demand is higher for medications for mental illnesses, cost effectiveness is key in the RCEP, where the demand is focused on treating infectious diseases,” ScinoPharm Taiwan Ltd (台灣神隆) cofounder Hardy Chan (詹維康) said.
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
CROSS-STRAIT TENSIONS: The US company could switch orders from TSMC to alternative suppliers, but that would lower chip quality, CEO Jensen Huang said Nvidia Corp CEO Jensen Huang (黃仁勳), whose products have become the hottest commodity in the technology world, on Wednesday said that the scramble for a limited amount of supply has frustrated some customers and raised tensions. “The demand on it is so great, and everyone wants to be first and everyone wants to be most,” he told the audience at a Goldman Sachs Group Inc technology conference in San Francisco. “We probably have more emotional customers today. Deservedly so. It’s tense. We’re trying to do the best we can.” Huang’s company is experiencing strong demand for its latest generation of chips, called
GLOBAL ECONOMY: Policymakers have a choice of a small 25 basis-point cut or a bold cut of 50 basis points, which would help the labor market, but might reignite inflation The US Federal Reserve is gearing up to announce its first interest rate cut in more than four years on Wednesday, with policymakers expected to debate how big a move to make less than two months before the US presidential election. Senior officials at the US central bank including Fed Chairman Jerome Powell have in recent weeks indicated that a rate cut is coming this month, as inflation eases toward the bank’s long-term target of two percent, and the labor market continues to cool. The Fed, which has a dual mandate from the US Congress to act independently to ensure